Humacyte, Inc.
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology company developing and manufacturing off-the-shelf, bioengineered human tissues, initially focused on acellular tissue engineered vessels (ATEVs) for vascular repair and replacement. Its FDA-approved product, Symvess, is used in adults with extremity… From the company’s description.
In fiscal 2025, Humacyte, Inc. reported revenue of $2.04M and a net loss of $40.83M. Operations used $105.04M in cash. Over the twelve months to Jun 30, 2026, revenue was $2.12M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Humacyte, Inc. does
In the company’s own words
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology company developing and manufacturing off-the-shelf, bioengineered human tissues, initially focused on acellular tissue engineered vessels (ATEVs) for vascular repair and replacement. Its FDA-approved product, Symvess, is used in adults with extremity arterial injuries when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible; its intended customers include hospitals and trauma centers. Humacyte is also developing ATEVs for hemodialysis access, peripheral artery disease, coronary bypass and pediatric heart surgery, and is exploring a vessel-based islet cell delivery system for Type 1 diabetes. The company reports its business as a single platform rather than describing reportable operating segments. Its proprietary process grows human vascular tissue and removes the cells, producing an implant designed for use across patients; production takes place at an 83,000-square-foot bioprocessing facility. As of December 31, 2025, ATEVs had been implanted in approximately 636 patients in clinical trials and expanded-access programs, in addition to commercial use. Its website is www.humacyte.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- DURHAM, NC
- Fiscal year end
- December
- CIK
- 1818382
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Humacyte, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Humacyte, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Humacyte, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Humacyte, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Humacyte, Inc.'s last four quarterly filings that the numbers alone won't show?”